Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TDP-43 Aggregation: The Healthy-Toxic Balance of the Prion-Like Domain.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Gpnmb defines a phagocytic state of microglia linked to cell death in prion disease mouse model.

Nature communications·2026
Same author

Serum NfL and GFAP in post-COVID syndrome: minimal evidence of CNS injury after adjusting for confounders.

Frontiers in cellular neuroscience·2026
Same author

ALS motor phenotypes: a revised 'OPM' classification.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

Loss-of-function variants in the CAPN1 activator CD99L2 cause X-linked spastic ataxia.

Nature communications·2026
Same author

Blocking RAN translation without altering repeat RNAs rescues <i>C9ORF72</i>-related ALS and FTD phenotypes.

Science (New York, N.Y.)·2026

Related Experiment Video

Updated: Aug 9, 2025

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.3K

TDP-43 Proteinopathy Specific Biomarker Development.

Isabell Cordts1, Annika Wachinger1, Carlo Scialo2

  • 1Department of Neurology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, 81675 Munich, Germany.

Cells
|February 25, 2023
PubMed
Summary
This summary is machine-generated.

Researchers are developing biomarkers to detect TDP-43 proteinopathy in neurodegenerative diseases like ALS and FTD. Early detection of TDP-43 pathology is crucial for accurate diagnosis and targeted therapy development.

Keywords:
TDP-43amyotrophic lateral sclerosisbiofluidbiomarkercerebrospinal fluiddementiafrontotemporal dementianeurodegeneration

More Related Videos

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

8.8K
An Optimized Quantitative Pull-Down Analysis of RNA-Binding Proteins Using Short Biotinylated RNA
07:55

An Optimized Quantitative Pull-Down Analysis of RNA-Binding Proteins Using Short Biotinylated RNA

Published on: February 17, 2023

3.9K

Related Experiment Videos

Last Updated: Aug 9, 2025

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.3K
Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

8.8K
An Optimized Quantitative Pull-Down Analysis of RNA-Binding Proteins Using Short Biotinylated RNA
07:55

An Optimized Quantitative Pull-Down Analysis of RNA-Binding Proteins Using Short Biotinylated RNA

Published on: February 17, 2023

3.9K

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Neurodegenerative Diseases

Background:

  • TDP-43 proteinopathy is a key feature in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and limbic age-related TDP-43 encephalopathy (TATE).
  • Current diagnostic methods often rely on clinical presentation, leading to uncertain pathological classifications.
  • TDP-43 pathology significantly impacts patient stratification and the development of targeted therapies.

Purpose of the Study:

  • To review recent advancements in developing TDP-43-specific biomarkers.
  • To explore the potential of these biomarkers for in vivo detection of TDP-43 proteinopathy.
  • To assess the utility of biomarkers in stratifying patients and guiding therapeutic strategies.

Main Methods:

  • Review of current literature on TDP-43 proteinopathy.
  • Analysis of pathophysiological processes underlying TDP-43 accumulation.
  • Investigation of biomarker candidates using biosamples from relevant clinical entities.

Main Results:

  • Emerging biomarkers show promise for detecting TDP-43 pathology during a patient's lifetime.
  • Biomarker development is essential for differentiating between clinical syndromes with shared TDP-43 pathology.
  • Progress is being made in identifying and validating TDP-43-specific detection methods.

Conclusions:

  • Development of TDP-43 biomarkers is critical for accurate diagnosis and patient stratification in neurodegenerative diseases.
  • Biomarkers will facilitate the development and application of therapies targeting TDP-43 proteinopathy.
  • Further research and validation are needed to translate biomarker candidates into clinical practice.